Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic …
Alpha Tau Medical Ltd. announced that an abstract presenting combined safety and efficacy data from three clinical studies evaluating Alpha DaRT treatment for pancreatic cancer has been accepted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract pools data from 58 patients across studies conducted in Canada and Israel.
Alpha Tau Medical Ltd. announced that an abstract entitled 'Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer' has been accepted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from May 29 to June 2, 2026. The abstract presents a pooled analysis of safety and efficacy data from three prospective clinical studies evaluating Alpha DaRT treatment in patients with pancreatic ductal adenocarcinoma (PDAC). The studies were conducted at centers in Canada and Israel, enrolling a total of 58 patients. The abstract is expected to be published on the ASCO conference website on May 21, 2026, at 5:00 PM ET. The ASCO Annual Meeting is the world's largest and most prestigious medical oncology conference, attracting tens of thousands of leading oncologists and researchers.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.